Paragon Care Ltd (PGC)
Australian Securities Exchange · Australia · prices in AUD · close of 20 Oct 2026
Key indicators
| Last close | AUD 0.150 |
|---|---|
| 52-week range | 0.125 – 0.325 |
| Return, 1 month / 3 months | +7.1% / +15.4% |
| Return, 1 year / 3 years | −49.2% / −16.7% |
| Trend | Below its 200-day average |
| RSI (14) | 60 |
| Volatility (1 year) | 60.5% |
| Worst drawdown (1 year) | -61.5% |
| Average daily value traded | 0.06M AUD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Paragon Care is an Australian healthcare company that supplies medical equipment, devices and consumables to healthcare providers. Its customers include hospitals, aged care facilities and primary care practices, which rely on the company for products used in patient care and clinical settings. Paragon Care is based in Australia and operates as a distributor and provider of healthcare products and related services across the local market.
Paragon Care Ltd trades under the code PGC on the Australian Securities Exchange in Australia, with its price quoted in Australian dollars (AUD). Our dividend records, which start in 2019, show payments in 4 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Paragon Care Ltd (PGC) trades on the Australian Securities Exchange in Australia. It last closed at AUD 0.150 on 20 October 2026.
Its price-based Market X-Ray is 51 out of 100 (a fair price profile), ranking 903 of 1,815 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 49.2% and over the last three months it rose 15.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 44 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -7.2% | ||
| From 52-week high | -53.8% | ||
| Momentum | 55 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 15.4% | ||
| 6-month return | -6.3% | ||
| 12-month return, skipping the last month | -52.5% | ||
| Stability (higher is calmer) | 50 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 60.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -61.5% | ||
| Liquidity | 57 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.06M AUD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 2 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +3.4% |
|---|---|
| 1 month | +7.1% |
| 3 months | +15.4% |
| 6 months | −6.3% |
| 1 year | −49.2% |
| 3 years | −16.7% |
| 5 years | −47.2% |
Signals
| 50-day / 200-day average | 0.139 / 0.162 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.008 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 Sep 2023 | AUD 0.0060 |
| 14 Mar 2023 | AUD 0.0060 |
| 12 Sep 2022 | AUD 0.0060 |
| 21 Mar 2022 | AUD 0.0060 |
| 13 Sep 2021 | AUD 0.0100 |
| 21 Mar 2019 | AUD 0.0110 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.